vicadrostat (BI 690517) / Boehringer Ingelheim - LARVOL DELTA

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=416 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease (clinicaltrials.gov) - P3 | N=11800 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Cardiovascular • Congestive Heart Failure • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys: Contrasting effects of once versus twice daily dosing. (PubMed, J Pharmacol Exp Ther) - "Here, the study describes key preclinical studies with the novel aldosterone synthase inhibitor vicadrostat that were instrumental in the design of early clinical studies and provide insight into predicted and unpredicted pharmacodynamic effects. These observations will inform further development of vicadrostat and related drugs for the treatment of kidney disease and other metabolic disease-related morbidities."

Journal • PK/PD data • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • CYP11B1

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors-A Systematic Review. (PubMed, Basic Clin Pharmacol Toxicol) - "A significant suppression of cortisol production was found for LCI699 (osilodrostat) but not for baxdrostat, lorundrostat, BI 690517 (vicadrostat) or dexfadrostat. We conclude that ASIs have promising BP-lowering effects with very limited effects on cortisol production and offer reno-protective effects in chronic kidney disease. Studies on hypertensive target organ damage and cardiovascular outcomes are, however, lacking."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Fibrosis • Hypertension • Immunology • Nephrology • Novel Coronavirus Disease • Renal Disease

A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease (clinicaltrials.gov) - P3 | N=11800 | Not yet recruiting | Sponsor: Boehringer Ingelheim

Head-to-Head • New P3 trial • Cardiovascular • Congestive Heart Failure • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure (clinicaltrials.gov) - P3 | N=6000 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Nov 2027 ➔ May 2028 | Trial primary completion date: Nov 2027 ➔ May 2028

Head-to-Head • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Vicadrostat with and without empagliflozin reduces albuminuria across KDIGO risk class in chronic kidney disease (ERA 2025) - P2, P3 | "Vicadrostat with and without empagliflozin reduced albuminuria across KDIGO risk class in chronic kidney disease. Vicadrostat given in combination with empagliflozin shows promise as a potential treatment option for patients with CKD that will undergo further testing in a Phase 3 trial program (EASi-KIDNEYTM, NCT06531824)."

Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Effects of vicadrostat with and without empagliflozin in people with chronic kidney disease by baseline BMI (ERA 2025) - P2, P3 | "Vicadrostat with or without empagliflozin reduced albuminuria irrespective of baseline BMI dichotomized at 30 kg/m2 in participants with CKD and with or without type 2 diabetes. Vicadrostat given in combination with empagliflozin shows promise as a potential treatment option for patients with CKD that will undergo further testing in a phase 3 trial program (EASi-KIDNEYTM, NCT06531824)."

Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

ISS1.3 Reducing aldosterone: can we protect kidneys and hearts? (ERA 2025) - "The second segment presents phase 2 data from the combined treatment of vicadrostat and empagliflozin, demonstrating a significant reduction in aldosterone levels and the urinary albumin-to-creatinine ratio (UACR) in patients with Chronic Kidney Disease (CKD). The final part underscores the interconnectedness of heart and kidney diseases, proposing that reducing aldosterone synthesis could also benefit patients with Heart Failure (HF).The session advocates for a collaborative approach among specialties to effectively address these diseases. The symposium concludes by emphasizing the centrality of the patient in these discussions, reinforcing the need for patient-centric strategies in disease management"

Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Fibrosis • Heart Failure • Hypertension • Immunology • Inflammation • Nephrology • Renal Disease

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart (clinicaltrials.gov) - P3 | N=4200 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Cardiovascular • Congestive Heart Failure • Heart Failure

Insights from the vicadrostat phase 2 study and implications for further clinical development (HEART FAILURE 2025) - "Sponsored by Boehringer Ingelheim"

Clinical • P2 data • Cardiovascular

Exploring the Potential Health Economic Value of the Aldosterone Synthase inhibitor and Sodium Glucose Transporter 2 inhibitor Combination in Chronic Kidney Disease (ISPOR 2025) - P2, P3 | "The simulation modeling suggests the vicadrostat+empagliflozin combination may offer a promising new option in CKD treatment with meaningful cost savings for health systems through improved patient outcomes and avoidance of complications. Clinical outcomes of the ongoing phase 3 trial (EASi-KIDNEY™, NCT06531824) will be essential to confirm these findings."

HEOR • Chronic Kidney Disease • Nephrology • Renal Disease

New Therapies for the Management of Chronic Kidney Disease. (PubMed, Cureus) - "Aldosterone synthase inhibitors (ASIs), such as vicadrostat, may represent a new horizon in selectively inhibiting aldosterone synthesis while preserving cortisol production. Early-phase trials have shown reductions in albuminuria and a potential for renal protection. The question is, could ASIs emerge as a fifth pillar in CKD management and help curb the progression?"

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart (clinicaltrials.gov) - P3 | N=4200 | Not yet recruiting | Sponsor: Boehringer Ingelheim

Head-to-Head • New P3 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=416 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P2 trial • Chronic Kidney Disease • Nephrology • Renal Disease

Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors. (PubMed, Curr Opin Nephrol Hypertens) - "In the coming years, nonsteroidal MR antagonists and aldosterone synthase inhibitors are likely to play an increasingly large role in routine medical practice to help improve cardiovascular and kidney outcomes."

Journal • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) (clinicaltrials.gov) - P3 | N=11000 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Jan 2029 ➔ Aug 2028 | Trial primary completion date: Jan 2029 ➔ Aug 2028

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease

Aldosterone Synthase Inhibitor BI 690517: Specificity for Mineralocorticoid Receptor. (PubMed, Cardiol Rev) - "A new class of drugs to consider are the aldosterone synthase inhibitors, which inhibit salt and water reabsorption and decrease sympathetic stimulation. The ideal candidate drug must be capable of inhibiting the MR while sparing the glucocorticoid receptor, a challenge given the 95% homology of these receptors."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Nephrology

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) (clinicaltrials.gov) - P3 | N=11000 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Aug 2028 ➔ Jan 2029 | Trial primary completion date: Aug 2028 ➔ Jan 2029

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease

Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "BI 690517 was well tolerated and demonstrated dose-dependent inhibition of aldosterone synthesis. Larger studies are warranted to confirm these findings."

Journal • P1 data • PK/PD data • Chronic Kidney Disease • Hypotension • Nephrology • Renal Disease

CUMULATIVE EFFECTS OF THE ALDOSTERONE SYNTHASE INHIBITOR VICADROSTAT COMBINED WITH EMPAGLIFLOZIN ON ALBUMINURIA IN PEOPLE WITH CKD (ISN-WCN 2025) - P3 | "Combination of an ASi with an SGLT2 inhibitor is a promising, novel therapy strategy that may afford superior benefits over aldosterone synthase or SGLT2 inhibition alone and will be tested further in a phase III clinical trial (EASi-KIDNEY,NCT06531824). This abstract was also submitted to theASN 2024congress as ' Cumulative effects of aldosterone synthase and SGLT2 inhibition on albuminuria in people with CKD' ."

Chronic Kidney Disease • Nephrology • Renal Disease

A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood (clinicaltrials.gov) - P1 | N=15 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion